MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today that it has submitted the non-clinical section of the rolling submission of a New Drug Application (NDA) for omacetaxine mepesuccinate (formerly known as Ceflatonin®) to the U.S. Food and Drug Administration (FDA).
